MANGOCEUTICALS, INC. (MGRX): debt financing — Mangoceuticals sells $100K Series B preferred, borrows $500K at 18% from Indigo Capital

MANGOCEUTICALS, INC.

Sold 100 shares of Series B Convertible Preferred at $100K; stated value $1,100/share, convertible at $1.50 into up to 73,333 common shares.
Purchaser granted right to participate in any subsequent financing for 18 months from closing.
Borrowed $500K from Indigo Capital LP via Promissory Note at 18% annual interest compounded monthly, maturing April 15, 2026.
Prepayment premium equals interest to stated maturity; mandatory prepayment on qualified financing; default triggers acceleration and additional interest.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

MANGOCEUTICALS, INC. incurred loan of $500,000 with Indigo Capital LP at 18% per annum, compounded monthly maturing April 15, 2026.

Instrument: loan
Principal: $500,000
Counterparty: Indigo Capital LP
Rate: 18% per annum, compounded monthly
Maturity: April 15, 2026
Event: incurrence

Exact text from the filing

The Company's entry into the Promissory Note represents a direct financial obligation in the principal amount of $500,000, plus applicable interest, fees, and potential prepayment premiums and default payments, as described above.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-005263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.